Baxter International Inc. (NYSE: BAX) is paying $900 million to buy Sigma-Tau Finanziaria SpA’s Oncaspar unit, which makes medication to treat leukemia.

The acquisition is one of several we've seen as companies try to build up their cancer-treatment offerings. For more, see New Cancer Drugs Spark Deal Possibilities.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.